The investment will focus on developing gelatin and HPMC facilities, creating over 200 new jobs, and strengthening ACG’s 25-year presence in the US, with operations expected to begin in early 2027.
Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of the decade.
Two globally oriented drugmakers, Pfizer and Sanofi, are making moves that some may interpret as attempts to allay the pharma industry‘s reputation for being “only in it for the money” but could potentially benefit poorer countries if all goes to plan.
After a roller coaster ride entailing months of on again-off again negotiations with US president Donald Trump over drug prices, the country’s pharmaceutical industry is licking its wounds and gearing up for a fight.
